I like ABT and PFE better (see below) and didn’t think I needed to own three Big Pharma. A few details:
• NVS has opted to not be a player in branded generics, missing out on the biggest worldwide growth driver of the drug/biotech industry (#msg-61960596). In emerging markets, NVS will sell only patented branded drugs and generic generics, limiting its growth opportunities in such markets.
• NVS grossly overpaid for Alcon, which was such an expensive deal that it fundamentally changed the configuration of the parent company.
• Recent quality screw-ups at multiple manufacturing plants suggest a possible JNJ-like problem with QA that could snowball into something serious.
• NVS’ flagship new drug, Gilenya, has already hit a sales plateau in the US market (#msg-77810032). It will be a decent-selling drug, but hardly a Diovan-like blockbuster.
• NVS missed the HCV market entirely by backing a series of failures such as NM283, ANA975, Albuferon, and (probably) DEB025.
• All told, NVS remains a fine company (and I might reenter some point); however, ABT and PFE currently represent better value and have a stronger tie-in with The Global Demographic Tailwind.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.